- InnoScot Health supports the new regulatory roadmap released by MHRA, calling it a crucial step towards making the pathway for medical device innovation safer and more accessible for patients.
- The roadmap outlines timelines for implementing the UK’s future core regulations over the next two years, with priority measures to protect patient safety and accessibility expected to be implemented this year and the core regulations of the new framework planned to be in place by 2025.
- The new regulatory roadmap aims to provide greater visibility, enhance the UK’s ability to benefit from rapidly advancing medical technology, and deliver greater alignment with international regulatory requirements to support system readiness and minimize the risk of supply disruption for UK patients.
InnoScot Health, a leading medical technology company, has pledged its support for the Medicines and Healthcare products Regulatory Agency’s (MHRA) new regulatory roadmap for medical devices in the UK. The roadmap, known as Tofido, outlines the agency’s plans for implementing a new regulatory framework for medical devices in the UK following Brexit.
The Tofido roadmap aims to ensure that the UK’s regulatory system for medical devices remains robust and streamlined following the country’s departure from the European Union. It includes plans for new legislation, regulatory guidance, and an improved system for market surveillance and vigilance.
InnoScot Health has welcomed the Tofido roadmap, highlighting the importance of a clear and effective regulatory framework for the medical device industry. The company believes that the new roadmap will provide greater clarity and certainty for medical device manufacturers, as well as ensuring the safety and efficacy of medical devices for patients in the UK.
“We fully support the MHRA’s Tofido roadmap for medical device regulation in the UK. We believe that a robust and efficient regulatory framework is essential for the success of the medical device industry, and we are committed to working with the MHRA to ensure the smooth implementation of the new regulatory system,” said a spokesperson for InnoScot Health.
The company also emphasized the importance of maintaining close collaboration between the UK and the EU in the regulation of medical devices, to ensure continued alignment and cooperation in this vital area.
InnoScot Health’s backing of the Tofido roadmap reflects the broader industry support for the MHRA’s efforts to establish a world-leading regulatory framework for medical devices in the UK. The company’s commitment to regulatory compliance and patient safety underscores the value of the Tofido roadmap for the UK’s medical device industry.